Abivax SA Sponsored ADR (NASDAQ:ABVX) Stock Has Average Price Target of $156.38

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been given an average recommendation of “Moderate Buy” by the sixteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $156.69.

ABVX has been the topic of a number of recent research reports. Leerink Partners lifted their price target on shares of Abivax from $140.00 to $148.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research report on Friday, July 17th. Citizens Jmp reissued a “market outperform” rating and issued a $187.00 target price on shares of Abivax in a research note on Wednesday, July 1st. Barclays reissued an “overweight” rating and issued a $148.00 price target on shares of Abivax in a research report on Tuesday. Finally, Wall Street Zen downgraded Abivax from a “hold” rating to a “sell” rating in a research report on Saturday.

Abivax Price Performance

NASDAQ:ABVX opened at $91.06 on Monday. Abivax has a one year low of $69.81 and a one year high of $148.83. The company has a fifty day moving average price of $117.40 and a 200 day moving average price of $117.12. The stock has a market cap of $7.95 billion, a P/E ratio of -15.03 and a beta of 0.96.

Abivax (NASDAQ:ABVX) last released its earnings results on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The company had revenue of $1.37 million for the quarter, compared to analyst estimates of $0.80 million. As a group, equities research analysts anticipate that Abivax will post -4.18 EPS for the current year.

Institutional Trading of Abivax

A number of institutional investors have recently bought and sold shares of ABVX. Versant Capital Management Inc acquired a new position in Abivax in the second quarter valued at about $30,000. GHP Investment Advisors Inc. boosted its position in shares of Abivax by 155.6% during the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after purchasing an additional 140 shares in the last quarter. Assetmark Inc. boosted its position in shares of Abivax by 41.5% during the first quarter. Assetmark Inc. now owns 886 shares of the company’s stock worth $99,000 after purchasing an additional 260 shares in the last quarter. Troluce Capital Advisors LLC acquired a new position in shares of Abivax in the 2nd quarter valued at $133,000. Finally, Clearstead Advisors LLC bought a new stake in shares of Abivax in the 4th quarter valued at $138,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

About Abivax

Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.

Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn’s disease.